Zelira Therapeutics to outline progress of Zenivol™ and HOPE™ at Proactive’s medical cannabis webinar on Aug 11

By Deputy Chief EditorAugust 7, 2020

187 2 minutes read

Zelira Therapeutics Ltds (ASX:ZLD) (OTCQB:ZLDAF) managing director and chief executive officer Richard Hopkins will outline the companys plan to launch its its Zenivol and HOPE range of products into the Australian market by the end of the third quarter 2020.

It is also targeting to launch HOPE for autism in Louisiana in the third quarter of 2020.

The developer of clinically validated cannabinoid-derived medicines, is reaching a major milestone as it accelerates its transition from a purely research-based organisation to become a revenue-generating company.

The company generated its maiden revenues from its first US licensing deal in the first quarter of 2020

Zelira is undertaking product development programs targeting specific conditions and human clinical trial programs focused on insomnia, autism and opioid reduction in patients with chronic non-cancer pain.

Product pipeline[hhmc]

Zeliras commercialisation plans are focused on the launch of up to five different products into global markets in the second half of 2020.

These include the Zenivol and HOPE range of products in Australia, an aged care formulation, which is expected to launch at the end of the year in the US and a new over-the-counter (OTC) product line that will launch in the US in the next quarter.

Zeliras commercialisation plans are focused on the launch of up to five different products into global markets in the second half of 2020.

The company has developed two proprietary formulations (HOPE), which have already been launched and generating revenues in Pennsylvania.

Zelira is continuing to progress discussions with third parties aimed at licensing its products, including HOPE and Zenivol, in the US.

Well-funded to accelerate launch of products[hhmc]

The company is well-funded to leverage its unique Launch, Learn and Develop model to launch products, generate revenues and progress development of clinically validated medicines.

In early August, Zelira raised a total of A$8.75 million through the oversubscribed placement of 175 million shares at A$0.05 per share, improving the companys cash position to around A$10.35 million, before costs.

The funds raised will be used to accelerate Zeliras plans to launch multiple products into global markets and to advance its planned clinical programs.